中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
18期
45-46,47
,共3页
海藻酸钠%微球栓塞剂%多发性子宫肌瘤%卵巢功能%安全性
海藻痠鈉%微毬栓塞劑%多髮性子宮肌瘤%卵巢功能%安全性
해조산납%미구전새제%다발성자궁기류%란소공능%안전성
sodiunl alginate%uterine artery embolization%multiple fibroid%ovarian function%safety
目的：观察海藻酸钠微球血管栓塞剂用于多发性子宫肌瘤介入术后患者的临床疗效并评价其安全性。方法选取医院收治的患者200例，采用随机数字表法分为对照组和观察组，各100例。对照组患者给予传统手术治疗，观察组患者给予海藻酸钠微球血管栓塞剂治疗。结果治疗后3，6个月，观察组的总有效率均明显高于对照组（ P﹤0.05），子宫肌瘤体积的缩小情况均明显优于对照组（ P﹤0.05）；雌二醇（E2）、促卵泡激素（FSH）、促黄体生成素（LH）改善情况均明显优于对照组（ P﹤0.05）；两组患者治疗前阴道超声窦卵泡计数( APC )未见明显差异，对照组患者治疗3个月后较治疗前未见明显差异，治疗后6个月APC计数较治疗前明显下降（ P﹤0.05）；观察组患者治疗后3，6个月APC数量较治疗前均未见明显差异（ P﹥0.05）；观察组围绝经期症状发生率为6.67%，明显少于对照组的27.50%（χ2=15.2727，P=0.0001）；两组患者不良反应发生率比较，未见明显差异（ P﹥0.05）。结论海藻酸钠微球血管栓塞剂治疗多发性子宫肌瘤，能有效缩小子宫肌瘤体积，提高近期治疗效果，降低围绝经期症状的发生率，有助于患者卵巢功能的恢复，疗效显著。
目的：觀察海藻痠鈉微毬血管栓塞劑用于多髮性子宮肌瘤介入術後患者的臨床療效併評價其安全性。方法選取醫院收治的患者200例，採用隨機數字錶法分為對照組和觀察組，各100例。對照組患者給予傳統手術治療，觀察組患者給予海藻痠鈉微毬血管栓塞劑治療。結果治療後3，6箇月，觀察組的總有效率均明顯高于對照組（ P﹤0.05），子宮肌瘤體積的縮小情況均明顯優于對照組（ P﹤0.05）；雌二醇（E2）、促卵泡激素（FSH）、促黃體生成素（LH）改善情況均明顯優于對照組（ P﹤0.05）；兩組患者治療前陰道超聲竇卵泡計數( APC )未見明顯差異，對照組患者治療3箇月後較治療前未見明顯差異，治療後6箇月APC計數較治療前明顯下降（ P﹤0.05）；觀察組患者治療後3，6箇月APC數量較治療前均未見明顯差異（ P﹥0.05）；觀察組圍絕經期癥狀髮生率為6.67%，明顯少于對照組的27.50%（χ2=15.2727，P=0.0001）；兩組患者不良反應髮生率比較，未見明顯差異（ P﹥0.05）。結論海藻痠鈉微毬血管栓塞劑治療多髮性子宮肌瘤，能有效縮小子宮肌瘤體積，提高近期治療效果，降低圍絕經期癥狀的髮生率，有助于患者卵巢功能的恢複，療效顯著。
목적：관찰해조산납미구혈관전새제용우다발성자궁기류개입술후환자적림상료효병평개기안전성。방법선취의원수치적환자200례，채용수궤수자표법분위대조조화관찰조，각100례。대조조환자급여전통수술치료，관찰조환자급여해조산납미구혈관전새제치료。결과치료후3，6개월，관찰조적총유효솔균명현고우대조조（ P﹤0.05），자궁기류체적적축소정황균명현우우대조조（ P﹤0.05）；자이순（E2）、촉란포격소（FSH）、촉황체생성소（LH）개선정황균명현우우대조조（ P﹤0.05）；량조환자치료전음도초성두란포계수( APC )미견명현차이，대조조환자치료3개월후교치료전미견명현차이，치료후6개월APC계수교치료전명현하강（ P﹤0.05）；관찰조환자치료후3，6개월APC수량교치료전균미견명현차이（ P﹥0.05）；관찰조위절경기증상발생솔위6.67%，명현소우대조조적27.50%（χ2=15.2727，P=0.0001）；량조환자불량반응발생솔비교，미견명현차이（ P﹥0.05）。결론해조산납미구혈관전새제치료다발성자궁기류，능유효축소자궁기류체적，제고근기치료효과，강저위절경기증상적발생솔，유조우환자란소공능적회복，료효현저。
Objective To observe the clinical efficacy and safety of sodium alginate uterine artery embolization for treating multiple fi-broid. Methods Totally 200 patients admitted to the hospital were divided into the control group and the observation group according to the random number table method,100 cases in each group. The control group was given conventional surgical treatment,the observa-tion group was given sodium alginate uterine artery embolization. Results After 3,6 months of treatment,the total effective rate of the observation group was significantly higher than that of the control group( P ﹤ 0. 05);the shrink of uterine fibroid volume of the obser-vation group was significantly better than that of the control group( P ﹤ 0. 05);the E2,FSH,LH changes of the observation group were significantly lower than those of the control group( P ﹤ 0. 05);the APC between the two groups had no significant difference before treatment,the control group showed no significant difference after 3 months of treatment,and was significantly lower after 6 months of treatment than that before treatment( P ﹤ 0. 05);there was no statistically significant difference of APC in the observation group after 3,6 months of treatment( P ﹥ 0. 05). The incidence rate of menopausal symptoms of the observation group was 6. 67%,which was sig-nificantly less than 27. 50% of the control group (χ2=15. 272 7,P=0. 000 1). There was no significant difference in the incidence rate of adverse reactions between the two groups( P ﹥ 0. 05). Conclusion Sodium alginate uterine artery embolization in treating multi-ple fibroids can effectively reduce the volume of uterine fibroids,improve the therapeutic effect in the near future,reduce the periopera-tive incidence of menopausal symptoms,contribute to the recovery of ovarian function,with remarkable clinical effect.
